drug
midazolam
Marketedupdated 6mo agoby UCB SA
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Epilepsy
all catalysts(0)
nothing on the calendar yet
Trials studying midazolam
- phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- phase1A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
- phase2A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- phase1A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- phase1A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- phase1A Trial of Lu AH69593 in Healthy Participants
- phase1A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)
- phase1A Study of LY4355756 in Healthy Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 18, 2028
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jun 20, 2038formulationUS 10966990
- Jun 20, 2038formulationUS 10966990
- Jan 18, 2028formulationUS 82170331.2y
- Jan 18, 2028formulationUS 88093221.2y
- Jan 18, 2028formulationUS 92894321.2y
- Jan 18, 2028formulationUS 96874951.2y
FDA exclusivities (1)
- May 17, 2026ODE-243Orphan Drug (7y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that